Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CFD | P00746 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | PREP | P48147 | 1/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL344789 | 0.97 | PTGS1 (0.54) | PTGS1CYP3A4KMT2AGAATSHR | |
| Potassium Ion SCHEMBL9066983 | 0.85 | PTGS1 (0.51) | PTGS1CYP3A4GAATSHRALDH1A1 | |
| Potassium Ion SCHEMBL342725 | 0.84 | KMT2A (0.62) | CYP3A4KMT2AGAATSHRKDM4E | |
| SCHEMBL344495 | 0.83 | CYP3A4 (0.47) | PTGS1CYP3A4KMT2AGAATSHR | |
| SCHEMBL344635 | 0.82 | CYP3A4 (0.46) | PTGS1CYP3A4KMT2AGAATSHR | |
| SCHEMBL344790 | 0.82 | CYP3A4 (0.46) | PTGS1CYP3A4KMT2AGAATSHR | |
| Potassium Ion SCHEMBL5180749 | 0.78 | PTGS2 (0.49) | PTGS1KMT2AGAATSHRKDM4E | |
| Potassium Ion SCHEMBL8442247 | 0.78 | PTGS1 (0.55) | PTGS1KMT2AGAAALDH1A1POLB | |
| SCHEMBL12094224 | 0.75 | TSHR (0.60) | CYP3A4GAATSHRKDM4EALDH1A1 | |
| SCHEMBL218311 | 0.75 | PTGS2 (0.49) | PTGS1KMT2AGAATSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190192473-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Rosacea | AmDerma Pharmaceuticals, LLC | 2019-06-27 | — | — | US | disclosed |
| US-20190192474-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Skin Cancer | AmDerma Pharmaceuticals, LLC | 2019-06-27 | — | — | US | disclosed |
| US-10278941-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of glioma | AmDerma Pharmaceuticals, LLC (US) | 2019-05-07 | — | — | US | disclosed |
| US-10278940-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of skin cancer | AmDerma Pharmaceuticals, LLC (US) | 2019-05-07 | — | — | US | disclosed |
| US-20180028484-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Rosacea | AmDerma Pharmaceuticals, LLC | 2018-02-01 | — | — | US | disclosed |
| US-9592216-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of rosacea | AmDerma Pharmaceuticals, LLC (US) | 2017-03-14 | — | — | US | disclosed |
| US-20170065547-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Skin Cancer | ACTION MEDICINES, S.L. (ES) | 2017-03-09 | — | — | US | disclosed |
| US-9511044-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of skin cancer | AmDerma Pharmaceuticals, LLC (US) | 2016-12-06 | — | — | US | disclosed |
| US-9248114-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of hematological dyscrasias and cancer of an organ | ACTION MEDICINES, S.L. (ES) | 2016-02-02 | — | — | US | disclosed |
| US-9198886-B2 | Use of 2,5-dihydroxybenzene for the treatment of ocular diseases | CUEVAS SÁNCHEZ PEDRO (ES) | 2015-12-01 | — | — | US | disclosed |
| WO-2008020039-A2 | 2,5-DIHYDROXYBENZENE COMPOUNDS FOR TREATING CANCERS AND HEMATOLOGICAL DYSCRASIAS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008020027-A2 | 2,5-DIHYDROXYBENZENE COMPOUNDS FOR THE TREATMENT OF SKIN CANCER | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008020030-A1 | 2,5-DIHYDROXYBENZENE COMPOUNDS FOR THE TREATMENT OF PSORIASIS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008020028-A1 | 2,5 DIHYDROXYBENZENE COMPOUNDS FOR THE TREATMENT OF ROSACEA | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008020031-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF ANGIOGENIC DISEASES | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008020037-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING OBESITY, HIRSUTISM, HYPERTRICOSIS AND VIRAL WARTS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008020034-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF HEMANGIOMAS OR HEMANGIOBLASTOMAS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008020040-A2 | 2,5-DIHYDROXYBENZENE COMPOUNDS FOR THE TREATMENT OF FIBROSIS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008020033-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF ARTHRITIS AND PAIN | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008020025-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING ACTINIC KERATOSIS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190192473-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Rosacea | CYP8B1, CYP1B1, CYP26B1 | PTGS1 1355/4885CYP3A4 163/4885KMT2A 1430/4885 |
| US-10278940-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of skin cancer | CYP8B1, CYP26B1, CYP24A1 | PTGS1 1685/4885CYP3A4 220/4885KMT2A 878/4885 |
| US-20170065547-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Skin Cancer | CYP8B1, CYP26B1, CYP24A1 | PTGS1 1685/4885CYP3A4 220/4885KMT2A 878/4885 |
| US-20190192474-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Skin Cancer | CYP8B1, CYP26B1, CYP24A1 | PTGS1 1685/4885CYP3A4 220/4885KMT2A 878/4885 |
| US-20180028484-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Rosacea | CYP8B1, CYP1B1, CYP26B1 | PTGS1 1355/4885CYP3A4 163/4885KMT2A 1430/4885 |
| US-10278941-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of glioma | ALDH1A2, IDH3A, IDH3B | PTGS1 1089/4885CYP3A4 303/4885KMT2A 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.